Home Cart Sign in  
Chemical Structure| 965-52-6 Chemical Structure| 965-52-6

Structure of Nifuroxazide
CAS No.: 965-52-6

Chemical Structure| 965-52-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nifuroxazide suppresses the transcription activity of STAT1, STAT3 (IC50 = 3 μM in cells) and STAT5. It is a nitrofuran-based antidiarrheal agent that can prevent urinary tract infections.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nifuroxazide

CAS No. :965-52-6
Formula : C12H9N3O5
M.W : 275.22
SMILES Code : O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2
MDL No. :MFCD00079482

Safety of Nifuroxazide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319-H332-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Nifuroxazide

JAK-STAT

Isoform Comparison

Biological Activity

Target
  • STAT1

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 0, 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 40 μg/mL 24 or 48 hours To evaluate the effect of Nifuroxazide on HCC cell proliferation, migration, and apoptosis, results showed that Nifuroxazide significantly inhibited cell proliferation and migration while increasing apoptosis. Elife. 2024 Mar 5;12:RP90911.
Huh7 cells 0, 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 40 μg/mL 24 or 48 hours To evaluate the effect of Nifuroxazide on HCC cell proliferation, migration, and apoptosis, results showed that Nifuroxazide significantly inhibited cell proliferation and migration while increasing apoptosis. Elife. 2024 Mar 5;12:RP90911.
4T1 cells 0-20 µM 24, 48, 72 hours To evaluate the effect of Nifuroxazide on the viability of breast cancer cells, results showed that Nifuroxazide inhibited breast cancer cell viability in a concentration- and time-dependent manner. Cell Death Dis. 2015 Mar 26;6(3):e1701.
MCF-7 cells 0-20 µM 24, 48, 72 hours To evaluate the effect of Nifuroxazide on the viability of breast cancer cells, results showed that Nifuroxazide inhibited breast cancer cell viability in a concentration- and time-dependent manner. Cell Death Dis. 2015 Mar 26;6(3):e1701.
MDA-MB-231 cells 0-20 µM 24, 48, 72 hours To evaluate the effect of Nifuroxazide on the viability of breast cancer cells, results showed that Nifuroxazide inhibited breast cancer cell viability in a concentration- and time-dependent manner. Cell Death Dis. 2015 Mar 26;6(3):e1701.
MDA-MB-231 cells 0-20 µM 3 days To evaluate the inhibitory effect of Nifuroxazide combined with Palbociclib on cell proliferation, the results showed that the combination significantly inhibited cell proliferation. Cell Death Discov. 2023 Sep 26;9(1):355.
4T1 cells 0-20 µM 3 days To evaluate the inhibitory effect of Nifuroxazide combined with Palbociclib on cell proliferation, the results showed that the combination significantly inhibited cell proliferation. Cell Death Discov. 2023 Sep 26;9(1):355.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice H22 tumor-bearing mouse model IntratumOral injection 200 μg/mouse Once daily for 7 days To evaluate the anti-tumor effect of Nifuroxazide combined with radiotherapy in H22-bearing mice, results showed that the combination therapy significantly inhibited tumor growth, prolonged survival, and enhanced T lymphocyte activation and M1 macrophage polarization. Elife. 2024 Mar 5;12:RP90911.
Mice Acute graft-versus-host disease (aGvHD) model Intraperitoneal injection 200 μg/mouse Once daily for one week Combination with SAT05f significantly decreased the severity of aGvHD and prolonged the survival rate, reduced the activation of CD4+ effector T cells, increased Treg cells, and inhibited cytokine release. Cell Death Dis. 2016 Dec 1;7(12):e2507
Balb/C mice Lung metastasis model and abdominal metastasis model Oral 25 mg/kg and 50 mg/kg Once daily for 6 days Nifuroxazide significantly reduced tumor metastasis in lung and abdominal metastasis models Cell Death Dis. 2017 Jan 5;8(1):e2534
Balb/c mice 4T1 tumor model Intraperitoneal injection 25 mg/kg/d or 50 mg/kg/d Daily for 21 days To evaluate the inhibitory effect of Nifuroxazide combined with Palbociclib on tumor growth and lung metastasis, the results showed that the combination significantly inhibited tumor growth and lung metastasis. Cell Death Discov. 2023 Sep 26;9(1):355.
BALB/c mice 4T1 tumor model Intraperitoneal injection 50 mg/kg/day Once daily for 24 days To evaluate the effect of Nifuroxazide on 4T1 tumor growth and pulmonary metastasis, results showed that Nifuroxazide significantly inhibited tumor growth and pulmonary metastasis without detectable toxicity. Cell Death Dis. 2015 Mar 26;6(3):e1701.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.63mL

0.73mL

0.36mL

18.17mL

3.63mL

1.82mL

36.33mL

7.27mL

3.63mL

References

 

Historical Records

Categories